Analytical Data
-
Gene name
CDH22
- Application
-
Alternative Names
PB-cadherin; C20orf25; Pituitary and brain cadherin
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UJ99
-
Expression Region
Trp64~Phe277
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDH22, a member of the cadherin family, is a type of cell adhesion molecule that plays a crucial role in the regulation of cellular interactions and signaling. This protein is primarily expressed in the nervous system and has been implicated in neuronal development and synaptic function. The significance of CDH22 in synapse formation and maintenance highlights its potential role in neurodevelopmental disorders and neurodegenerative diseases. Recent studies suggest that alterations in CDH22 function may contribute to conditions such as autism spectrum disorders and schizophrenia. Given its involvement in critical brain functions, researchers are increasingly focused on characterizing CDH22 through recombinant protein techniques to better understand its structure, binding properties, and interaction with other cellular components. Producing recombinant CDH22 allows for detailed biochemical and biophysical analysis, which can aid in elucidating its mechanisms of action and potential therapeutic targets. The study of CDH22 not only advances our understanding of cadherin-mediated cell adhesion but also opens new avenues for exploring its role in various neurological conditions, making it a significant focus for future research in neurobiology and pharmacology.
